{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:12:22Z","timestamp":1788790342254,"version":"build-2803163510"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamainternmed.2018.6112","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T11:11:39Z","timestamp":1547032299000},"page":"224","source":"Crossref","is-referenced-by-count":36,"title":["Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect"],"prefix":"10.1001","volume":"179","author":[{"given":"Michael","family":"Fralick","sequence":"first","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Eliot Phillipson Clinician Scientist Training Program, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chana A.","family":"Sacks","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"ioi180104r1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"ioi180104r2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11606-018-4344-7","article-title":"Application and impact of run-in studies.","volume":"33","author":"Fralick","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"11","key":"ioi180104r3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"ioi180104r4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2013.280416","article-title":"Improving the quality of cancer care in an aging population: recommendations from an IOM report.","volume":"310","author":"Hurria","year":"2013","journal-title":"JAMA"},{"issue":"22","key":"ioi180104r5","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"ioi180104r9","first-page":"23","article-title":"The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration.","volume":"3","author":"King","year":"2013","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"7","key":"ioi180104r10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2165\/00023210-200822070-00001","article-title":"Pathological laughing and crying: epidemiology, pathophysiology and treatment.","volume":"22","author":"Wortzel","year":"2008","journal-title":"CNS Drugs"},{"issue":"5","key":"ioi180104r11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","article-title":"Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.","volume":"68","author":"Pioro","year":"2010","journal-title":"Ann Neurol"},{"issue":"12","key":"ioi180104r12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia.","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"ioi180104r15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2017.3919","article-title":"Use of health care databases to support supplemental indications of approved medications.","volume":"178","author":"Fralick","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"3","key":"ioi180104r17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"ioi180104r18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eurpsy.2004.09.031","article-title":"Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects: consensus paper of the European Alzheimer Disease Consortium.","volume":"20","author":"Robert","year":"2005","journal-title":"Eur Psychiatry"},{"issue":"19","key":"ioi180104r19","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1001\/jama.2012.36918","article-title":"Nonpharmacologic management of behavioral symptoms in dementia.","volume":"308","author":"Gitlin","year":"2012","journal-title":"JAMA"},{"key":"ioi180104r20","doi-asserted-by":"publisher","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study.","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"issue":"7","key":"ioi180104r21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-2788.2010.01275.x","article-title":"Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription.","volume":"54","author":"de Kuijper","year":"2010","journal-title":"J Intellect Disabil Res"},{"issue":"6","key":"ioi180104r22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/0706743717727240","article-title":"Antipsychotic use with and without comorbid psychiatric diagnosis among adults with intellectual and developmental disabilities.","volume":"63","author":"Lunsky","year":"2018","journal-title":"Can J Psychiatry"},{"issue":"1","key":"ioi180104r23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population.","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"9369","key":"ioi180104r24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"22","key":"ioi180104r25","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs atypical antipsychotic medications.","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi180104r26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"ioi180104r27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"7","key":"ioi180104r28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archinte.167.7.676","article-title":"Variation in nursing home antipsychotic prescribing rates.","volume":"167","author":"Rochon","year":"2007","journal-title":"Arch Intern Med"},{"issue":"11","key":"ioi180104r29","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/jama.2015.18286","article-title":"Dextromethorphan-quinidine for agitation in Alzheimer disease.","volume":"315","author":"Newman","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"ioi180104r30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.2018.11439","article-title":"Medicare spending on brand-name combination medications vs their generic constituents.","volume":"320","author":"Sacks","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"ioi180104r31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/jnnp.59.1.55","article-title":"Prevalence and clinical correlates of pathological affective display in Alzheimer\u2019s disease.","volume":"59","author":"Starkstein","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"ioi180104r32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/15622970701639445","article-title":"Inappropriate crying and laughing in Parkinson disease and movement disorders.","volume":"10","author":"Siddiqui","year":"2009","journal-title":"World J Biol Psychiatry"},{"issue":"8","key":"ioi180104r33","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1007\/s00415-010-5550-3","article-title":"Pseudobulbar affect: prevalence and quality of life impact in movement disorders.","volume":"257","author":"Strowd","year":"2010","journal-title":"J Neurol"},{"issue":"7","key":"ioi180104r34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12325-011-0031-3","article-title":"Pseudobulbar affect: an under-recognized and under-treated neurological disorder.","volume":"28","author":"Work","year":"2011","journal-title":"Adv Ther"},{"issue":"3","key":"ioi180104r35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MLR.0000000000000640","article-title":"Utilization of positive and negative controls to examine comorbid associations in observational database studies.","volume":"55","author":"Desai","year":"2017","journal-title":"Med Care"},{"key":"ioi180104r36","doi-asserted-by":"crossref","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study.","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"ioi180104r37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s40471-017-0121-0","article-title":"Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.","volume":"4","author":"Connolly","year":"2017","journal-title":"Curr Epidemiol Rep"},{"issue":"3","key":"ioi180104r38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.v99.3","article-title":"The FDA\u2019s Sentinel Initiative: a comprehensive approach to medical product surveillance.","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ioi180104r6","unstructured":"EllisB, HickenM. The little red pill being pushed on the elderly: CNN investigation exposes inappropriate use of drug in nursing homes. https:\/\/www-m.cnn.com\/2017\/10\/12\/health\/nuedexta-nursing-homes-invs\/index.html. Updated October 12, 2017. Accessed August 10, 2018."},{"key":"ioi180104r7","unstructured":"FDA Center for Drug Evaluation and Research. Medical review application number: 021879Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/021879Orig1s000MedR.pdf. April 30, 2010. Accessed August 10, 2018."},{"key":"ioi180104r8","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Nuedexta [drug label]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021879s000lbl.pdf. October 29, 2010. Accessed August 10, 2018."},{"key":"ioi180104r13","unstructured":"Optum. Real-world data portal. https:\/\/www.optum.com\/solutions\/life-sciences\/explore-data\/advanced-analytics.html. Accessed November 10, 2018."},{"key":"ioi180104r14","unstructured":"IBM Watson Health. Research data and analytic tools: Truven health analytics. https:\/\/truvenhealth.com\/markets\/life-sciences\/products\/data-tools. Accessed August 10, 2018."},{"key":"ioi180104r16","unstructured":"Centers for Medicare and Medicaid Services. 2015 Medicare drug spending dashboard. https:\/\/www.cms.gov\/research-statistics-data-and-systems\/statistics-trends-and-reports\/information-on-prescription-drugs\/2015medicare.html. Modified May 15, 2018. Accessed August 10, 2018."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2720138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T16:03:34Z","timestamp":1549296214000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.6112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.6112","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}